Clincosm LogoSign in Get a demo

An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)

Sponsor
Neuren Pharmaceuticals Limited (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05879614
Collaborator
(none)
20
Enrollment
1
Arm
12
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Prader-Willi Syndrome.

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

The primary purpose of this study is to investigate the safety, tolerability and pharmacokinetics of treatment with NNZ-2591 oral solution in children and adolescents with Prader-Willi Syndrome. The secondary purpose is to investigate measures of efficacy. Subjects will receive treatment with NNZ-2591 oral solution (50 mg/mL) doses for a total of 13 weeks.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)
Anticipated Study Start Date :
Jun 30, 2023
Anticipated Primary Completion Date :
Jun 30, 2024
Anticipated Study Completion Date :
Jun 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: NNZ-2591

NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.

Drug: NNZ-2591
NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
Other Names:
  • Cyclo-L-Glycyl-L-2-Allylproline

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Safety and Tolerability [13 weeks]

      To examine the incidence, severity and frequency of adverse events (AEs), including serious adverse events (SAEs) during treatment with NNZ-2591.

    2. Pharmacokinetic - Measurement of Cmax [13 weeks]

      Maximum observed concentration (Cmax) of NNZ-2591

    3. Pharmacokinetic - Measurement of AUC [13 weeks]

      Area under the concentration-time curve of NNZ-2591

    4. Pharmacokinetic - Measurement of time to Cmax [13 weeks]

      Time to Cmax of NNZ-2591

    5. Pharmacokinetic - Measurement of t1/2 [13 weeks]

      Apparent terminal elimination half-life of NNZ-2591

    Secondary Outcome Measures

    1. Exploratory efficacy measurement [13 weeks]

      Assessed by PWS-specific Clinical Global Impression Scale & Domain -Overall Improvement Score (CGI-I)

    2. Exploratory efficacy measurement [13 weeks]

      Assessed by Caregiver Global Impression-Change Score

    3. Exploratory efficacy measurement [13 weeks]

      Assessed by PWS-specific Clinical Global Impression Scale-Severity (CGI-S) Overall Score

    4. Exploratory efficacy measurement [13 weeks]

      Assessed by Caregiver Top 3 Concerns Likert Scale Scores

    5. Exploratory efficacy measurement [13 weeks]

      Assessed by PWS Profile Score

    6. Exploratory efficacy measurement [13 weeks]

      Assessed by PWS Anxiousness and Distress Behaviors Questionnaire Score (PADQ)

    7. Exploratory efficacy measurement [13 weeks]

      Assessed by Autism Diagnostic Observation Schedule (ADOS-2), Repetitive behaviors and Social scores

    8. Exploratory efficacy measurement [13 weeks]

      Assessed by Hyperphagia Questionnaire-Clinical Trials (HQ-CT) Score

    9. Exploratory efficacy measurement [13 weeks]

      Assessed by Food Safety Zone Questionnaire Score

    10. Exploratory efficacy measurement [13 weeks]

      Assessed by Vineland Adaptive Behavior Scales-3 Growth Scale Scores

    11. Exploratory efficacy measurement [13 weeks]

      Assessed by Zarit Burden Interview Score

    12. Exploratory efficacy measurement [13 weeks]

      Assessed by Child Sleep Habits Questionnaire (CSHQ)

    13. Exploratory efficacy measurement [13 weeks]

      Assessed by Impact of Childhood Neurological Disability Scale (ICND)

    14. Exploratory efficacy measurement [13 weeks]

      Assessed by Quality of Life Inventory-Disability (QI-Disability)

    15. Exploratory efficacy measurement [13 weeks]

      Assessed by Kaufman Brief Intelligence Test or Mullen Scales of Early Learning

    16. Exploratory efficacy measurement [13 weeks]

      Assessed by PWS Suicidality Assessment

    17. Exploratory efficacy measurement [13 weeks]

      Assessed by Caregiver Diary

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    4 Years to 12 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    1. Clinical diagnosis of PWS with a documented disease-causing genetic abnormality of the chromosome 15q11-q13 confirmed by DNA methylation and microarray.

    2. Males or females aged 4-12 years, inclusive.

    3. Body weight of 12 kg to 100kg (inclusive) at Baseline.

    4. Subjects with a Clinical Global Impression - Severity (CGI-S) score of 4 or greater at the Screening visit.

    5. Must currently be on treatment with growth hormone.

    6. Each subject must be able to swallow the study medication provided as a liquid solution.

    7. Caregiver(s) must have sufficient English language skills.

    8. Subject and caregiver must reside in the US and have been resident in the US for at least 3 months prior to screening.

    Exclusion Criteria:

    1. Body weight <12 kg or >100 kg at Baseline.

    2. HbA1c values above 7% at the Screening visit.

    3. Clinically significant abnormalities in safety laboratory tests and vital signs at Screening.

    4. Positive pregnancy test at the Screening visit.

    5. Positive drugs of abuse screen not explained by concomitant medications.

    6. Abnormal QTcF interval or prolongation at Screening.

    7. Any other clinically significant finding on ECG at the Screening visit.

    8. Positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Screening or Baseline.

    9. Previous COVID 19 infection with last 12 months that required hospitalization.

    10. Previous COVD-19 infection involving multi-organ systems, resulting in Multisystem Inflammatory Syndrome in Children (MIS-C) or with clinically significant long term effects.

    11. COVID-19 infection associated with acute kidney injury (AKI) or renal conditions.

    12. Renal conditions or abnormalities identified in laboratory testing, imaging or medical history.

    13. Liver conditions and Hepatic abnormalities.

    14. Vision abnormalities and Ocular conditions.

    15. Excluded concomitant treatments.

    16. Unstable seizure profile.

    17. Current clinically significant cardiovascular, gastrointestinal, or respiratory disease, or clinically significant organ impairment, or endocrine disease with the exception of obesity and controlled hypothyroidism.

    18. Current clinically significant hypo or hyperthyroidism, Type 1 or Type 2 diabetes mellitus requiring insulin (whether well controlled or uncontrolled), or uncontrolled Type 1 or Type 2 diabetes.

    19. Has planned surgery during the study.

    20. History of, or current, cerebrovascular disease or brain trauma.

    21. History of, or current catatonia or catatonia-like symptoms.

    22. History of, or current, malignancy.

    23. Current major or persistent depressive disorder (including bipolar depression).

    24. Significant uncorrected hearing impairment.

    25. Allergy to strawberry.

    26. Has participated in another interventional clinical study within 30 days prior to start of Screening.

    27. Subject is judged by the Investigator or Medical Monitor to be inappropriate for the study.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Neuren Pharmaceuticals Limited

    Investigators

    • Study Director: James Shaw, Neuren Pharmaceuticals

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Neuren Pharmaceuticals Limited
    ClinicalTrials.gov Identifier:
    NCT05879614
    Other Study ID Numbers:
    • NEU-2591-PWS-001
    First Posted:
    May 30, 2023
    Last Update Posted:
    May 30, 2023
    Last Verified:
    May 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Neuren Pharmaceuticals Limited
    Prader-Willi Syndrome
    Additional relevant MeSH terms:
    Prader-Willi Syndrome
    Syndrome

    Study Results

    No Results Posted as of May 30, 2023